Vivian Clark, MD
Internal Medicine · Elizabethton, TNNPI 1205889508
Payments from drug & device makers
Across 58 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$308
- UCB, Inc.$143
- Neurocrine Biosciences, Inc.$136
- Johnson & Johnson$101
- Novartis$82
- Sumitomo Pharma America, Inc.$82
- plus $462 from 14 others
What the payments were for
- Food & beverage$1,313100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 9 | $308 |
| UCB, Inc. | 1 | $143 |
| Neurocrine Biosciences, Inc. | 3 | $136 |
| Johnson & Johnson | 7 | $101 |
| Novartis | 5 | $82 |
| Sumitomo Pharma America, Inc. | 1 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $64 |
| AbbVie(2 entities) | 5 | $62 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| GSK | 3 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Pfizer | 3 | $35 |
| Sun Pharmaceutical Industries Inc. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $28 |
| Astellas Pharma US Inc | 1 | $22 |
| Lilly USA, LLC | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nayzilam$143
How this compares
$1,313 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,414 | $247,616 |
| NuplazidPimavanserin Tartrate | 35 | $92,235 |
| IngrezzaValbenazine Tosylate | 29 | $88,478 |
| Invega SustennaPaliperidone Palmitate | 15 | $53,723 |
| XareltoRivaroxaban | 290 | $46,024 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $42,795 |
| AustedoDeutetrabenazine | 24 | $38,176 |
| EntrestoSacubitril/Valsartan | 161 | $31,421 |
| NuedextaDextromethorphan Hbr/Quinidine | 47 | $30,737 |
| TrulicityDulaglutide | 50 | $29,097 |
| OzempicSemaglutide | 26 | $26,956 |
| MyrbetriqMirabegron | 170 | $26,638 |
| LinzessLinaclotide | 41 | $24,128 |
| XifaxanRifaximin | 15 | $21,661 |
| JardianceEmpagliflozin | 119 | $21,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $35 | $247,6161,414 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $101 | $99,747305 claims |
| Acadia Pharmaceuticals IncNuplazid | $308 | $92,23535 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $136 | $88,47829 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $38 | $58,448103 claims |
| NovartisEntresto | $82 | $31,421161 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $36 | $30,73747 claims |
| Lilly USA, LLCTrulicity | $16 | $29,09750 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $26,638170 claims |
| AbbVieLinzess | $62 | $24,12841 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $64 | $21,66115 claims |
| Boehringer IngelheimJardiance | $28 | $21,418119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Elizabethton
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.